Skip to main content

VISP: Center for Viral Infection Structural Proteomics

Go Search
VISP: Center for Viral Infection Structural Proteomics
SARS-CoV
Influenza virus
Herpesvirus
Flaviviruses
Poxviruses
  
VISP: Center for Viral Infection Structural Proteomics > VISPCollaboratorPublications > Development of novel antivirals against flaviviruses  

VISPCollaboratorPublications: Development of novel antivirals against flaviviruses

Title

Development of novel antivirals against flaviviruses 

Authors

Patkar CG, et al. 

Abstract

Dengue virus is responsible for a significant amount of human disease in predominantly tropical areas of the world. Much effort has focused on the development of vaccines against the four serotypes of dengue, and within the next few years a vaccine is anticipated. Less progress has been made at developing antivirals that might reduce disease severity. Recent advances in the structural biology of dengue virus and other flaviviruses have opened new possibilities for the rational design of small molecule inhibitors of virus replication. This chapter describes the structural attributes of the dengue virion and how knowledge of its structure, assembly, and entry mechanisms are guiding new strategies toward the development of compounds that will interfere with the viral replication process.

Journal

Novartis Found. Symp. 

Date

8/10/2006 

Link

PMID: 17319153 

Reference

Patkar CG, Kuhn RJ. Development of novel antivirals against flaviviruses. Novartis Found Symp. (2006);277:41-52; discussion 52-6, 71-3, 251-3.

PMID

17319153  

Keyword

VISP, FLAVI 
Attachments
Created at 3/1/2007 5:32 PM  by Sophie Coon 
Last modified at 3/1/2007 5:32 PM  by Sophie Coon